57 related articles for article (PubMed ID: 19952776)
1. Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrofiban Safety study.
Schiariti M; Saladini A; Missiroli B; Papalia F; Cuturello D; Puddu PE; Gaudio C
J Cardiovasc Med (Hagerstown); 2010 Apr; 11(4):250-9. PubMed ID: 19952776
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
[TBL] [Abstract][Full Text] [Related]
3. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M; Campo G; de Cesare N; Meliga E; Vranckx P; Furgieri A; Angiolillo DJ; Sabatè M; Hamon M; Repetto A; Colangelo S; Brugaletta S; Parrinello G; Percoco G; Ferrari R;
Circulation; 2009 Jun; 119(25):3215-22. PubMed ID: 19528337
[TBL] [Abstract][Full Text] [Related]
4. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
[TBL] [Abstract][Full Text] [Related]
5. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
Valgimigli M; Percoco G; Barbieri D; Ferrari F; Guardigli G; Parrinello G; Soukhomovskaia O; Ferrari R
J Am Coll Cardiol; 2004 Jul; 44(1):14-9. PubMed ID: 15234398
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
[TBL] [Abstract][Full Text] [Related]
7. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
[TBL] [Abstract][Full Text] [Related]
8. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.
Danzi GB; Capuano C; Sesana M; Baglini R
Catheter Cardiovasc Interv; 2004 Feb; 61(2):179-84. PubMed ID: 14755808
[TBL] [Abstract][Full Text] [Related]
9. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
Li W; Fu X; Xue H; Wang Y; Wang X; Zhao Y; Geng W; Yang Z; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
Cardiovasc Ther; 2013 Aug; 31(4):210-4. PubMed ID: 22954393
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.
Schiariti M; Saladini A; Cuturello D; Missiroli B; Puddu PE
J Cardiovasc Med (Hagerstown); 2011 Jan; 12(1):29-36. PubMed ID: 20639765
[TBL] [Abstract][Full Text] [Related]
13. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
14. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
[TBL] [Abstract][Full Text] [Related]
15. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
van 't Hof AW; Ernst N; de Boer MJ; de Winter R; Boersma E; Bunt T; Petronio S; Marcel Gosselink AT; Jap W; Hollak F; Hoorntje JC; Suryapranata H; Dambrink JH; Zijlstra F;
Eur Heart J; 2004 May; 25(10):837-46. PubMed ID: 15140531
[TBL] [Abstract][Full Text] [Related]
16. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
Dobrzycki S; Kralisz P; Nowak K; Prokopczuk P; Kochman W; Korecki J; Poniatowski B; Zuk J; Sitniewska E; Bachorzewska-Gajewska H; Sienkiewicz J; Musial WJ
Eur Heart J; 2007 Oct; 28(20):2438-48. PubMed ID: 17884846
[TBL] [Abstract][Full Text] [Related]
17. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.
Akbulut M; Ozbay Y; Gundogdu O; Dagli N; Durukan P; Ilkay E; Arslan N
Curr Med Res Opin; 2004 Nov; 20(11):1759-67. PubMed ID: 15537476
[TBL] [Abstract][Full Text] [Related]
18. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
Huynh T; Piazza N; DiBattiste PM; Snapinn SM; Wan Y; Pharand C; Theroux P
Int J Cardiol; 2005 Apr; 100(1):73-8. PubMed ID: 15820288
[TBL] [Abstract][Full Text] [Related]
19. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
[TBL] [Abstract][Full Text] [Related]
20. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
